Cytek BiosciencesCTKB +0.22%71 Forward PE Ratio is 370.28 as of Jul. 03, 2026. GuruFocus rates CTKB with a GF Score™ of 71/100 and a GF Value™ of $5.82 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 392 Medical Devices & Instruments companies, Cytek Biosciences ranks worse than 98.21% on this metric.
Cytek Biosciences (NAS:CTKB) Forward PE Ratio Explanation
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
Cytek Biosciences Forward PE Ratio Related Terms
Cytek Biosciences Forward PE Ratio Historical Data
* Premium members only.
The historical data trend for Cytek Biosciences's Forward PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cytek Biosciences Forward PE Ratio Chart
Cytek Biosciences Annual Data
Trend
2021-12
2024-12
Forward PE Ratio
370.37
110.17
Cytek Biosciences Quarterly Data
2021-12
2024-12
Forward PE Ratio
370.37
110.17
CTKB vs CERS, NPCE, CLPT: Forward PE Ratio Comparison
For the Medical Devices subindustry, Cytek Biosciences's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cytek Biosciences Forward PE Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Cytek Biosciences's Forward PE Ratio distribution charts can be found below:
* The bar in red indicates where Cytek Biosciences's Forward PE Ratio falls into.
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
Cytek Biosciences (CTKB) has a Forward PE Ratio of 370.28 as of Jul. 03, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Cytek Biosciences and its competitors. According to the industry distribution chart, Cytek Biosciences ranks #385 out of 392 companies in the Medical Devices & Instruments industry, placing it in the top 98.2%.
Is Cytek Biosciences' Forward PE Ratio too high?
Cytek Biosciences' current Forward PE Ratio is 370.28. The Medical Devices & Instruments industry median Forward PE Ratio is 19.24. Cytek Biosciences' value of 370.28 is 1824.5% above this industry median. Based on the distribution chart, Cytek Biosciences ranks #385 out of 392 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Cytek Biosciences has a GF Score™ of 71/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Cytek Biosciences' Forward PE Ratio compare to CERS and NPCE?
According to the Medical Devices & Instruments industry distribution chart, Cytek Biosciences ranks #385 out of 392 companies for Forward PE Ratio. This places Cytek Biosciences in the lower half of its industry. The industry median Forward PE Ratio is 19.24. Cytek Biosciences' value of 370.28 is 1824.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Medical Devices & Instruments company?
The median Forward PE Ratio among Medical Devices & Instruments companies is 19.24, based on 392 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cytek Biosciences's current Forward PE Ratio of 370.28 is 1824.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Cytek Biosciences and its competitors. For the Medical Devices & Instruments industry, the median Forward PE Ratio is 19.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cytek Biosciences's current Forward PE Ratio is 370.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cytek Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Cytek Biosciences (CTKB) is currently considered Modestly Undervalued. The stock's GF Value™ is $5.82, compared to a current price of $4.59 — trading 21.1% below its estimated fair value. The current Forward PE Ratio is 370.28 and 1824.5% above the Medical Devices & Instruments industry median of 19.24. Cytek Biosciences' overall GF Score™ is 71/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For Cytek Biosciences (CTKB), the current Forward PE Ratio is 370.28 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cytek Biosciences (CTKB) Overvalued in 2026?
Based on GuruFocus' analysis, Cytek Biosciences stock appears to be undervalued.
The current stock price of $4.59 is trading 21.1% below its estimated GF Value™ of $5.82.
GuruFocus considers Cytek Biosciences to be Modestly Undervalued.
Key valuation signals for CTKB:
Forward PE Ratio: 370.28
GF Value™: $5.82 vs. price of $4.59 (21.1% below fair value)
Industry Position: 1824.5% above the Medical Devices & Instruments median (#385 of 392)
No single metric tells the full story. See the CTKB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of research and clinical tools with its novel technical approach of leveraging the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its patented FSP technology optimizes sensitivity and accuracy through its optical and electronic designs that utilize an inventive method of light detection and distribution to a specifically selected number and type of detectors. Its FSP cell analyzers, the Cytek Aurora, Northern Lights, and Cytek Aurora Evo systems, deliver high-resolution, high-content and high-sensitivity cell analysis and address the inherent limitations of other technologies.
71GF Score
Get the complete analysis for CTKB
Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CTKB has been successfully added to your 